Jump to content

Home

DUKEHealth JA

Open menu
Cart
  • DUKEHealth JA login

Bookmark/Search this post

  • Facebook logo Facebook
  • Twitter logo Twitter
  • LinkedIn logo LinkedIn
  • Forward logo Forward
  • Home
  • About Us
  • Activity Application
    • Activity Requirements
    • Credit Offered by Learner Type
    • Disclosure Form
  • Help Center
    • Course Admin Resources
    • Duke CE RSS Recordings
    • Learner Resources
    • Maintenance of Certification (MOC)
    • CE Logos
  • Contact Us
  • My Transcript

You are here

Home

Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18

Sessions

Session Date
Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18 Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma 02/13/2018 - 8:00am to 9:00am EST
Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18 What We’ve Accomplished and Where We’re Going Home Transplant and PPOP 03/13/2018 - 8:00am to 9:00am EDT
Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18 Depth of Response in Multiple Myeloma A Pooled Analysis of Three PETHEMA/GEM Clinical Trials Journal Club 03/27/2018 - 8:00am EDT to 04/03/2018 - 9:00am EDT
Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18 Development of Clinician Scientists from the Outer Banks to the Singapore Straits 05/08/2018 - 8:00am to 9:00am EDT
Cellular Therapy & Hematologic Malignancies Grand Rounds - FY18 06/05/2018 - 8:00am to 9:00am EDT

Pages

  • « first
  • ‹ previous
  • 1
  • 2

Features

  • Home
  • Sessions

 © 2025 Duke University Health System Disclaimer Duke & Your Privacy

Powered by the EthosCE Learning Management System, a continuing education LMS.
    • Home
    • About Us
    • Activity Application
      • Activity Requirements
      • Credit Offered by Learner Type
      • Disclosure Form
    • Help Center
      • Course Admin Resources
      • Duke CE RSS Recordings
      • Learner Resources
      • Maintenance of Certification (MOC)
      • CE Logos
    • Contact Us
    • My Transcript